Haematology
Silence Therapeutics PLC’s clinical research is centred on polycythemia vera, a chronic myeloproliferative neoplasm characterised by excessive red blood cell production and elevated haematocrit.
- Polycythemia vera
- Myeloproliferative neoplasms
- Haematocrit control
The sponsor’s activity in this area reflects a focused interest in blood disorders requiring ongoing clinical management and monitoring.
Red Cell Mass Regulation
Its trial portfolio includes investigation of therapies aimed at controlling erythrocytosis and reducing the need for phlebotomy in patients with persistent elevation of blood counts.
- Erythrocytosis
- Phlebotomy reduction
- Blood count management
These interests place emphasis on clinical endpoints tied to maintaining safer haematocrit levels and limiting repeated venesection procedures.
RNA-Targeted Therapeutics
The sponsor is involved in research on RNA interference-based treatment approaches, with attention to gene silencing strategies relevant to disorders driven by abnormal gene expression.
- RNA interference
- Gene silencing
- Subcutaneous administration
This therapeutic domain aligns with a precision-focused approach to modifying disease pathways in haematological disease.
Clinical Management of Chronic Blood Disorders
Research activity also extends to the practical management of chronic myeloproliferative disease, where sustained control of symptoms and treatment burden is clinically important.
- Chronic disease management
- Myeloproliferative disease
- Treatment burden
Interest in this area is reflected in outcomes related to maintaining haematocrit below target thresholds without repeated intervention.
